HUL’s investment case rises above this short-term disruption: HUL’s structural appeal lies beyond the defensiveness it offers amid Covid-19 disruption,…
India business saw strong growth; FY21/22e EPS up 7.5/7.3%; outlook for US is bright; TP raised to Rs 770.
Covid-19 related gains are largely priced in; Aurobindo, Biocon are top picks; Torrent downgraded to ‘Hold’.
While Q1 will bear brunt of lockdown, FY21 earnings likely to be among best in consumer sector; TP up to…
FY20-22e Ebitda cut by 2-12% due to the impact of Covid-19; TP revised to Rs 90.
Q4 is likely to be subdued; FY20-22 EPS down 3-12% to factor in Covid-19; stock’s attractively priced; TP cut to…
Despite near-term impact, growth story remains intact; FY21-22 EPS cut by average 20%; TP down to Rs 3,750.
FY20/21/22e Ebitda down 4.1/15.1/4.5%; TP cut to Rs 1,550; ‘Buy’ maintained.
Multiple potential triggers could yield substantial returns; given challenges, TP reduced to Rs 500 from Rs 770; ‘Buy’ maintained.
While some effect of COVID-19 is expected in Q4, Q1FY21 may face material impact; ‘Buy’ retained with TP of Rs…
Fears of a large change in estimates are overdone; FY21/22e EPS down 8/5% due to lower downstream margins; TP cut…
Prospects for existing and under-construction malls is bright; TP raised to Rs 1,110.
While we earlier liked Cipla for its stable outlook in focus markets, India and South Africa, we now believe it…
L&T InfoTech’s Q2FY19 revenues came in below street expectation with constant currency growth of 3.5% and reported revenues of 2.7%…
On 27 March 2018 the Board of Fortis Healthcare (FHL) approved the demerger from and sale of its hospital business…
Cipla the preferred pick in challenging environment, on a comfortable India and EM base and strong US growth outlook
Earnings estimates for FY18-20 raised 15-30%; Upgraded to ‘Buy’; TP rises to Rs 1,600 from Rs 900 with rollover to…
DBEL reported volumes of 7.6mt for 1HFY18, up 6.3% y-o-y. Although volume growth was significantly lower compared with c20% y-o-y…
